Navigation Links
Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvox's Patient Share in the Treatment of Nosocomial Pneumonia
Date:9/22/2008

Most Important Factors Driving Nosocomial Pneumonia Prescribing in

Hospitals Are Infectious Disease Consults and ATS/IDSA Guidelines

Arlington Medical Resources and Decision Resources Introduce the New

Hospital Anti-Infectives Insight Series

MALVERN, Penn. and WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that over 80 percent of surveyed hospital physicians estimate that if approved, Basilea/Johnson & Johnson's ceftobiprole will steal, on average, nearly a third of Pfizer's Zyvox patient share in the treatment of nosocomial pneumonia. In addition, several product profiles that are analogous to ceftobiprole and other antibiotics were presented to physicians to see how they would compete within the nosocomial pneumonia drug market. The new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia found that the ceftobiprole analogue profile is well positioned to compete in this drug market.

"We presented several antibiotic product profiles to physicians we surveyed that are analogous to ceftobiprole, Forest's ceftaroline in combination with a beta-lactamase inhibitor and Theravance/Astellas's telavancin to assess the potential positioning of these agents in the future nosocomial pneumonia market," states John Lebbos, M.D., Vice President of Infectious Diseases at Decision Resources. "Physicians were highly receptive to these profiles -- in fact, 67 percent of physicians indicated that the ceftobiprole analogue profile is well positioned to compete in the large empiric, first-line therapy market for nosocomial pneumonia."

The report also finds that hospital prescribing patterns are mainly driven by an institution's infectious disease consults and by guidelines presented by the American Thoracic Society (ATS) and the Infectious Disease Society of America (IDSA). A hospital's protocol and local guidelines play the next important role. Therefore, key stakeholders such as hospital infectious disease specialists and clinicians developing an institution's guidelines typically have broad influence on prescribing well beyond their own patients.

AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

2008 Hospital Anti-Infective Insight Series reports include:

-- Hospital Anti-Infective Insight Series: Nosocomial Pneumonia

-- Hospital Anti-infective Insight Series: Skin & Soft Tissue Infections

-- Hospital Anti-Infective Insight Series: U.S. Antibiotic Usage Patterns

and Drivers in the ICU Setting

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources; Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Physicians Reconsider Implications of Enhance Trial
6. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
7. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
8. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
11. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each January, ... to access the treadmills. It’s a predictable trend. After the excesses of November and ... in shape by joining gyms, starting new walking or running routines, or signing up ...
Breaking Medicine News(10 mins):